6505--Pylarify 2026 F-18 Injection 512-C60151

The Department of Veterans Affairs, through Network Contract Office 5, awarded a firm-fixed-price delivery order to Progenics Pharmaceuticals, Inc. for the procurement of Pylarify (Piflufolastat F-18) Injection. This radiopharmaceutical is used by the Nuclear Medicine Department at the Baltimore VA Medical Center for PET imaging to detect metastatic prostate cancer. The contract, issued under Federal Supply Schedule contract 36F79725D0093, has a total value of $599,047.52 for an estimated 166 units per year at a unit price of $3,608.72. The award was finalized on January 30, 2026, with deliveries scheduled on an as-needed basis from Monday through Friday. This acquisition was conducted as a sole-source award under GSAM/R 538.7104-3(b) because Progenics Pharmaceuticals, Inc. is the sole FDA-authorized manufacturer of Pylarify. The justification for the sole-source selection is based on the product's unique clinical utility, specifically its 110-minute half-life, which provides greater scheduling flexibility and diagnostic consistency compared to alternative agents. Progenics Pharmaceuticals, Inc., a certified small business, is responsible for the manufacturing and delivery of the product to the Baltimore VA Medical Center, where the government performs final inspection and acceptance based on FDA and VHA oncology guidelines.